Food and Drug Administration approval is seen as a gateway to potential coverage by Medicare and commercial insurers for Grail's Galleri test.
Pricing remains a key watch item, as it's far from clear how commercial insurers will value the test.
Grail (NASDAQ:GRAL) stock has been highly volatile in 2026, and that trend looks set to continue next year as well. Management expects its multi-cancer early detection (MCED) test, Galleri, to be approved in the first quarter of 2027, but that's only part of the story. Here's what investors need to know and where the stock could be heading next year.
The company finalized its pre-market approval submission for Galleri in late January, only to follow up with disappointing top-line results from its landmark three-year trial of Galleri with England's National Health Service (NHS). The trial failed to meet its primary endpoint of a statistically significant reduction in the diagnosis of late-stage (III and IV) cancers in a population of 142,000.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The principle was that Galleri would detect cancers at an early stage (I and II), leading to less expensive, less intrusive, and more comfortable treatments and, ultimately, better patient outcomes. The trial's overall failure obviously raised concerns about FDA approval and, more importantly, insurer coverage of the test. That's the crash you can see in the stock in February.
While the trial's result was disappointing across the more than 50 cancers it tests for, it did demonstrate more compelling data across the 12 most deadly cancers (including anus, bladder, colorectal, head and neck, lung, ovary, pancreas, and stomach) that cause two-thirds of the deaths in the U.S.
As such, management continued to build the case that the Galleri test data were compelling enough to convince the FDA to approve the test and spur insurer adoption. It's a case that management highlighted at the American Society of Clinical Oncology (ASCO) meeting at the end of May, when outlining both the NHS trial and a smaller 35,000-patient trial in the U.S. and Canada.
Image source: Getty Images.
The stock then soared in September after an FDA panel voted in favor of Galleri's safety, effectiveness, and benefit, paving the way for FDA marketing approval in 2027.
The ultimate adoption of Galleri by insurers and medical bodies relies on a somewhat complex set of factors and criteria that don't lend themselves to a binary assessment of trial results. For example, a medical insurer is highly likely to conduct a cost-benefit analysis, weighing the benefits of early detection against the test's cost relative to alternative tests and the cost of false positives.
False positives not only cause significant and unnecessary stress in a patient population, but they also create unnecessary costs, as the positively tested patients will undergo more costly and specific diagnostic testing to determine whether they have cancer with a higher degree of accuracy.
Readers interested in more detail on such matters can read an analysis of the two Galleri trial results in a previous article. Suffice it to say that it isn't simply a matter of the FDA approving the Galleri test and insurers adopting it en masse; the test also needs to demonstrate its commercial viability to insurers.
Image source: Getty Images.
In addition, management has high hopes that Medicare will reimburse Galleri under the Nancy Sewell ACT, which allows coverage and payment for FDA-approved MCED tests if the Centers for Medicare & Medicaid Services (CMS) "determines such coverage is appropriate."
Management is in contact with the CMS and expects it to initiate a National Coverage Analysis (NCA) following FDA approval (hopefully in early 2027), culminating in a National Coverage Determination (NCD) about a year later.
Therefore, the sequence of events next year is FDA approval, which then opens up more detailed conversations with commercial payers and insurers, and initiation of an NCA by the CMS. Ultimately, the key to Grail and Galleri's future may not be commercial payers' decision to adopt the test; it may come down to the price they are willing to pay for it. Grail's management thinks the Galleri test will ultimately settle in a $500 to $600 range, with Wall Street analysts modeling $574 in 2029.
That would be a favorable outcome for Grail, but there's a long way to go before it takes place, and the first step is FDA approval.
Before you buy stock in Grail, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Grail wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 22, 2026.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Grail. The Motley Fool has a disclosure policy.